Chiesi has agreed to acquire KalVista Therapeutics in a $1.9 billion deal that adds an approved oral therapy for hereditary angioedema to its rare-disease portfolio. Analysts cited the transaction as evidence of continued pharma appetite for oral treatments in immune-mediated rare conditions, with the acquisition landing during a busy week for biotech M&A. Under the terms reported, Chiesi will pay $27 per share for KalVista, representing a 40% premium to the stock’s closing price prior to announcement. The acquired product, Ekterly, is positioned for acute swelling attacks in people with hereditary angioedema. For KalVista and its shareholders, the deal is a liquidity event with a clear strategic rationale: bring an already commercially validated drug into a larger platform with distribution and development capabilities.